D
Intra-Cellular Therapies, Inc.
ITCI
$131.87
-$0.05-0.04%
D
Sell
3/14/2023Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and valuation index.
D
Sell
2/23/2023Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index and valuation index.
D
Sell
9/22/2022Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/22/2022 due to a decline in the total return index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/22/2022 due to a decline in the total return index and volatility index.
D
Sell
8/23/2022Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 8/23/2022 due to an increase in the volatility index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 8/23/2022 due to an increase in the volatility index and valuation index.
D
Sell
5/31/2022Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/31/2022 due to a major increase in the total return index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/31/2022 due to a major increase in the total return index and volatility index.
D
Sell
5/13/2022Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/5/2022Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and volatility index.
D
Sell
4/20/2022Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 9.91 to 8.11, and earnings per share declined from -$0.9453 to -$1.0523.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.02, the quick ratio declined from 9.91 to 8.11, and earnings per share declined from -$0.9453 to -$1.0523.
D
Sell
11/10/2021Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 11/10/2021 due to a noticeable increase in the growth index, total return index and valuation index. Total revenue increased 10.78% from $20.05M to $22.21M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 11/10/2021 due to a noticeable increase in the growth index, total return index and valuation index. Total revenue increased 10.78% from $20.05M to $22.21M.
D
Sell
11/8/2021Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index, growth index and volatility index. EBIT declined 29.92% from -$53.22M to -$69.14M, earnings per share declined from -$0.6515 to -$0.8463, and operating cash flow declined 24.2% from -$47.77M to -$59.33M.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index, growth index and volatility index. EBIT declined 29.92% from -$53.22M to -$69.14M, earnings per share declined from -$0.6515 to -$0.8463, and operating cash flow declined 24.2% from -$47.77M to -$59.33M.
D
Sell
5/6/2021Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 5/6/2021 due to a large decline in the total return index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 5/6/2021 due to a large decline in the total return index and valuation index.
D
Sell
4/16/2021Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 4/16/2021 due to an increase in the valuation index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 4/16/2021 due to an increase in the valuation index and volatility index.
D
Sell
2/16/2021Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 2/16/2021 due to a decline in the valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 2/16/2021 due to a decline in the valuation index.
D
Sell
2/1/2021Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 2/1/2021 due to an increase in the total return index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 2/1/2021 due to an increase in the total return index and volatility index.
D
Sell
1/15/2021Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 1/15/2021 due to a decline in the valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 1/15/2021 due to a decline in the valuation index.
D
Sell
11/12/2020Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 11/12/2020 due to an increase in the growth index, valuation index and solvency index. Total revenue increased 286.48% from $1.91M to $7.37M, the quick ratio increased from 10.19 to 19.18, and earnings per share increased from -$0.9591 to -$0.7937.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 11/12/2020 due to an increase in the growth index, valuation index and solvency index. Total revenue increased 286.48% from $1.91M to $7.37M, the quick ratio increased from 10.19 to 19.18, and earnings per share increased from -$0.9591 to -$0.7937.
D
Sell
9/15/2020Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/15/2020 due to a decline in the total return index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/15/2020 due to a decline in the total return index and valuation index.
D
Sell
8/31/2020Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 8/31/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 8/31/2020 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
8/14/2020Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 8/14/2020 due to a major decline in the total return index, growth index and solvency index. EBIT declined 32.16% from -$49.09M to -$64.87M, earnings per share declined from -$0.7282 to -$0.9591, and the quick ratio declined from 14.49 to 10.19.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 8/14/2020 due to a major decline in the total return index, growth index and solvency index. EBIT declined 32.16% from -$49.09M to -$64.87M, earnings per share declined from -$0.7282 to -$0.9591, and the quick ratio declined from 14.49 to 10.19.
D
Sell
7/22/2020Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 7/22/2020 due to a significant increase in the total return index, solvency index and growth index. Total revenue increased 1,687.95% from $60.6 to $1.08M, the quick ratio increased from 6.18 to 14.49, and debt to equity declined from 0.02 to 0.01.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 7/22/2020 due to a significant increase in the total return index, solvency index and growth index. Total revenue increased 1,687.95% from $60.6 to $1.08M, the quick ratio increased from 6.18 to 14.49, and debt to equity declined from 0.02 to 0.01.
D
Sell
5/1/2020Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, solvency index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, solvency index and valuation index.
D
Sell
1/7/2020Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 1/7/2020 due to a decline in the valuation index and growth index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 1/7/2020 due to a decline in the valuation index and growth index.
D
Sell
12/23/2019Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 12/23/2019 due to an increase in the volatility index and growth index. EBIT increased 7.14% from -$39.17M to -$36.38M, and earnings per share increased from -$0.6789 to -$0.6315.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 12/23/2019 due to an increase in the volatility index and growth index. EBIT increased 7.14% from -$39.17M to -$36.38M, and earnings per share increased from -$0.6789 to -$0.6315.
D
Sell
1/22/2019Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 1/22/2019 due to a decline in the total return index and volatility index.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 1/22/2019 due to a decline in the total return index and volatility index.
D
Sell
1/7/2019Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 1/7/2019 due to an increase in the total return index and valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 1/7/2019 due to an increase in the total return index and valuation index.
D
Sell
12/20/2018Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 12/20/2018 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 21.32 to 12.91.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D- from D on 12/20/2018 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 21.32 to 12.91.
D
Sell
9/29/2016Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/29/2016 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 10.75% from -$27.84M to -$30.83M, and total capital declined 5.92% from $452.74M to $425.96M.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 9/29/2016 due to a noticeable decline in the total return index, efficiency index and valuation index. Net income declined 10.75% from -$27.84M to -$30.83M, and total capital declined 5.92% from $452.74M to $425.96M.
D
Sell
7/5/2016Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 7/5/2016 due to a significant increase in the total return index, efficiency index and solvency index. Net income increased 3.44% from -$28.83M to -$27.84M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 7/5/2016 due to a significant increase in the total return index, efficiency index and solvency index. Net income increased 3.44% from -$28.83M to -$27.84M.
D
Sell
3/11/2016Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.1% from $501.85M to $476.24M.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.1% from $501.85M to $476.24M.
D
Sell
11/9/2015Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 11/9/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 146.53% from $203.57M to $501.85M, and net income increased 49.51% from -$21.51M to -$32.16M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D+ from D on 11/9/2015 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 146.53% from $203.57M to $501.85M, and net income increased 49.51% from -$21.51M to -$32.16M.
D
Sell
1/2/2015Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 1/2/2015 due to an increase in the efficiency index. Net income increased 41.51% from -$4.53M to -$6.42M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D from D- on 1/2/2015 due to an increase in the efficiency index. Net income increased 41.51% from -$4.53M to -$6.42M.
D
Sell
9/2/2014Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D- from E+ on 9/2/2014 due to an increase in the growth index and efficiency index. Total revenue increased 30.63% from $167.8 to $219.2, and EBIT increased 0.81% from -$4.57M to -$4.61M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to D- from E+ on 9/2/2014 due to an increase in the growth index and efficiency index. Total revenue increased 30.63% from $167.8 to $219.2, and EBIT increased 0.81% from -$4.57M to -$4.61M.
E
Sell
6/2/2014Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E+ from E on 6/2/2014 due to an increase in the valuation index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E+ from E on 6/2/2014 due to an increase in the valuation index.
E
Sell
5/12/2014Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E from E- on 5/12/2014 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 5.49 to 37.27, and total capital increased 351.44% from $31.62M to $142.73M.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E from E- on 5/12/2014 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 5.49 to 37.27, and total capital increased 351.44% from $31.62M to $142.73M.
E
Sell
5/5/2014Downgrade
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to E- from E on 5/5/2014 due to a large decline in the volatility index and growth index. Earnings per share declined from -$0.42 to -$0.3644.
Intra-Cellular Therapies, Inc. (ITCI) was downgraded to E- from E on 5/5/2014 due to a large decline in the volatility index and growth index. Earnings per share declined from -$0.42 to -$0.3644.
E
Sell
3/25/2014Upgraded
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E from on 3/25/2014 due to a significant increase in the solvency index, volatility index and growth index.
Intra-Cellular Therapies, Inc. (ITCI) was upgraded to E from on 3/25/2014 due to a significant increase in the solvency index, volatility index and growth index.
NASDAQ
04/01/2025 4:00PM Eastern
Quotes delayed
